Addressing the cause of autoimmune disease


Tolerion Platform

A novel platform that addresses the root cause of autoimmune disease, treating these chronic diseases in a fundamentally new way. Currently in clinical development with our first therapy, the Tolerion platform addresses autoimmune diseases directly at the immune system level.


Multiple Indications

A new approach to treating autoimmune disease with potential to treat those indications where the disease-causing self-antigen is identified; including type-1 diabetes, myasthenia gravis and neuromyelitis optica


Our Lead Compound: TOL-3021

TOL-3021, our lead product, is a tolerizing biologic in late-stage clinical development with potential to be the first disease-modifying therapeutic for type 1 diabetes